Skip to main content

PT-141 vs Kisspeptin-10

Both PT-141 and Kisspeptin-10 are used for sexual-health. Here's how their evidence, dosing, and regulatory status actually compare.

PT-141

Evidence A

Bremelanotide (Vyleesi)

A melanocortin receptor agonist that works directly on the nervous system to increase sexual desire. The only FDA-approved peptide for sexual dysfunction that acts on the brain rather than vascular system.

View full PT-141 profile →

Kisspeptin-10

Evidence B

Kisspeptin-10 (KP-10)

A 10-amino-acid neuropeptide that triggers GnRH release. Studied as a more physiologic alternative to hCG/GnRH for fertility, libido, and HPG-axis assessment.

View full Kisspeptin-10 profile →

Side-by-Side

AttributePT-141Kisspeptin-10
Evidence GradeAB
FDA StatusFDA-approved for hypoactive sexual desire disorder (HSDD) in womenNot FDA-approved — used in clinical research as a kisspeptin/GnRH stimulus test
Typical Dose1.75 mg subcutaneous, 45 min before activityTrial range: 0.1–10 mcg/kg IV/SC bolus
Clinics Indexed21011
Categoriessexual-healthsexual-health, fertility

Key reported benefits — PT-141

  • Increased sexual desire
  • CNS-mediated arousal
  • Works for both sexes (off-label for men)

Key reported benefits — Kisspeptin-10

  • GnRH/LH/FSH stimulation
  • Libido/arousal effects
  • HPG-axis testing

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons